Literature DB >> 22908175

In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.

Robert J Carman1, James H Boone, Harish Grover, Kimberly N Wickham, Li Chen.   

Abstract

We report the selection of Clostridium difficile resistant to the rifamycin class of antibiotics in a patient within 32 h of receiving rifaximin for the treatment of recurrent C. difficile diarrhea. Resistance was associated with single nucleotide substitutions within rpoB.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22908175      PMCID： PMC3486587          DOI： 10.1128/AAC.00974-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  In vivo selection of moxifloxacin-resistant Clostridium difficile.

Authors:  Ana Mena; Elena Riera; Carla López-Causapé; Irene Weber; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

2.  PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes.

Authors:  S L Stubbs; J S Brazier; G L O'Neill; B I Duerden
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

3.  A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.

Authors:  Kevin W Garey; Shashank S Ghantoji; Dhara N Shah; Musarat Habib; Vaneet Arora; Zhi-Dong Jiang; Herbert L DuPont
Journal:  J Antimicrob Chemother       Date:  2011-09-21       Impact factor: 5.790

4.  Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile.

Authors:  Ludovic Lemee; Anne Dhalluin; Sabrina Testelin; Marie-Andre Mattrat; Karine Maillard; Jean-François Lemeland; Jean-Louis Pons
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

5.  Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.

Authors:  Mark A Miller; Ruth Blanchette; Patrizia Spigaglia; Fabrizio Barbanti; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

6.  High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

Authors:  Scott R Curry; Jane W Marsh; Kathleen A Shutt; Carlene A Muto; Mary M O'Leary; Melissa I Saul; A William Pasculle; Lee H Harrison
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

7.  Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.

Authors:  Stuart Johnson; Christopher Schriever; Ursula Patel; Toral Patel; David W Hecht; Dale N Gerding
Journal:  Anaerobe       Date:  2009-08-18       Impact factor: 3.331

8.  Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus.

Authors:  H Aubry-Damon; C J Soussy; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

9.  Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.

Authors:  Jennifer R O'Connor; Minerva A Galang; Susan P Sambol; David W Hecht; Gayatri Vedantam; Dale N Gerding; Stuart Johnson
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191
  9 in total
  18 in total

Review 1.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

Review 2.  Rifamycins, Alone and in Combination.

Authors:  David M Rothstein
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

Review 3.  Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver.

Authors:  Philipp Lutz; Hans Dieter Nischalke; Christian P Strassburg; Ulrich Spengler
Journal:  World J Hepatol       Date:  2015-03-27

Review 4.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

5.  An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.

Authors:  E Bouza; L Alcalá; M Marín; M Valerio; E Reigadas; P Muñoz; M González-Del Vecchio; V de Egea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-13       Impact factor: 3.267

Review 6.  Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.

Authors:  Patrizia Spigaglia
Journal:  Ther Adv Infect Dis       Date:  2016-02

7.  Biofilm formation by Clostridium difficile.

Authors:  Tanja Dapa; Meera Unnikrishnan
Journal:  Gut Microbes       Date:  2013-07-25

8.  Antimicrobial Susceptibilities of Clostridium difficile Isolates from 12 Asia-Pacific Countries in 2014 and 2015.

Authors:  Tanya Lew; Papanin Putsathit; Kyung Mok Sohn; Yuan Wu; Kentaro Ouchi; Yoshikazu Ishii; Kazuhiro Tateda; Thomas V Riley; Deirdre A Collins
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

9.  Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden.

Authors:  Uyen T Dang; Idalia Zamora; Kirk E Hevener; Sudip Adhikari; Xiaoqian Wu; Julian G Hurdle
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 10.  Antimicrobial resistance in Clostridioides difficile.

Authors:  Keeley O'Grady; Daniel R Knight; Thomas V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-08-24       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.